Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
1 other identifier
interventional
200
0 countries
N/A
Brief Summary
Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2023
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2023
CompletedFirst Posted
Study publicly available on registry
March 24, 2023
CompletedStudy Start
First participant enrolled
June 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedMarch 24, 2023
March 1, 2023
1 year
March 8, 2023
March 13, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Measuring Toxoplasma igG and free testosterone in acne vulgaris patients and controls
Detect if the toxoplasma latent infection can be associated with disease severity and hormonal disturbances in acne vulgaris female patients
One month
Study Arms (2)
Toxoplasmosis seropositive female patients with active acne vulgaris
EXPERIMENTALToxoplasmosis seronegative in female patients with active acne vulgaris
EXPERIMENTALInterventions
Free testosterone levels and toxoplasma igG in serum by ELISA
Eligibility Criteria
You may qualify if:
- \- Female patients with active acne vulgaris
You may not qualify if:
- Patients with history of hormonal treatment Patients received anti toxoplasma therapy Patients with dermatological diseases caused by hormonal disturbances Pregnant and lactating patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Zienab Gamea Ali Ahmed
Study Record Dates
First Submitted
March 8, 2023
First Posted
March 24, 2023
Study Start
June 1, 2023
Primary Completion
June 1, 2024
Study Completion
December 1, 2024
Last Updated
March 24, 2023
Record last verified: 2023-03